FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
Read original at benzingaStocks · News reference
William Blair Initiates Coverage On Beta Bionics with Market Perform Rating
William Blair analyst Steven Lichtman initiates coverage on Beta Bionics (NASDAQ:BBNX) with a Market Perform rating.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 21, 2026, 8:15 PM
- Checked
- Aug 21, 2026, 8:15 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
William Blair initiates coverage on Tandem Diabetes Care and Beta Bionics, highlighting their growth potential in the insulin pump market.
Read original at benzingaBeta Bionics Affirms FY2026 Sales Guidance of $131.000M-$136.000M vs $133.305M Est
Read original at benzinga